Imagine my surprise when my limit order for $70 was executed for SDGR.
Any thoughts about the downside? I’m a new subscriber and the content and contributions are great. Thanks, Travis and friends.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More InfoYour subscription is paid through your PayPal account.
To update your credit card or cancel, please log in to PayPal.com, go to your automatic payments, open the Stock Gumshoe payment, and make changes there.
More information here: Paypal — What Is an Automatic Payment and How Do I Update or Cancel One?
In the short term, there’s almost no limit to the downside if sentiment for growth or biotech stories collapses in a real rout. The stock fell mostly because revenue guidance was wildly lower than analysts had expected, revenue is likely to grow unevenly over the next couple years, I expect, and the highest potential projects, the drugs they’re developing on their own, will take years to play out and consume a lot of the cash flow from the software business, so it could be a very bumpy ride.